Cannabis Science Inc. is an emerging cannabis pharmaceutical company that trades on the OTC Bulletin Board. They are at the forefront of medical marijuana research and development. With headquarters in Colorado Springs, California, the company works with world authorities on phytocannabinoid science targeting critical illnesses.
Phytocannabinoids – also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids – are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabis Science, Inc.’s dedication is to the creation of cannabis-based medicines. The company adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. They are working to create these medicines both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Cannabis has found use medicinally for thousands of years; however, until very recently little was known about how it actually worked. Some well-known uses of cannabis are for alleviating nausea, stimulating the appetite for people with AIDS and cancer, and reducing muscle spasms associated with neuromuscular disorders.
Cannabis Science, Inc. announced this month guidance on their product development and FDA Investigative New Drug Applications for their cannabis clinical trials. The Company is implementing their pharmaceutical grade cannabis product development and quality control standardizations through their licensed commercialization developer RockBrook Inc.
They are currently negotiating their laboratory quality control standardizations with another group. This will be a large contribution to the body of evidence presented as part of the Company’s Investigative New Drug Applications to the FDA for the critical ailments, which they will be pursuing through the FDA regulatory process.
Cannabis Science has a prioritized list of potential FDA Investigative New Drug Indications that they are researching. This includes Pain Management, Post Traumatic Stress Disorder (PTSD), Cancer, Influenza, and Asthma.
Chief Financial Officer Richard Cowan stated, “These much needed treatments for very serious health problems, such as cancer, AIDS, chronic pain, PTSD and many others, offer us the opportunity to grow this company into the major cannabis pharmaceutical firm it should be. The Cannabis Science business model – as a bridge between the medical marijuana world and pharmaceutical development — is unique, and places it in an excellent position to rise above the absurd stigmas and serious questions about medical cannabis.”
Let us hear your thoughts below: